Skip to main content
ESAIY logo

Eisai Co., Ltd. (ESAIY) Stock Price & Analysis

Eisai Co., Ltd. (ESAIY) — price $8.22 (+1.11%), as of the Nov 19, 2026 trading session; market cap $9.27B.

Educational signal · not a buy or sell recommendation · How to read this

$8.22 +$0.09 (+1.11%) Market Cap $9.27B

Eisai Co., Ltd. · ESAIY · Healthcare · Drug Manufacturers - Specialty & Generic

Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • AMRX · Amneal Pharmaceuticals, Inc. · 66 /100
  • RDY · Dr. Reddy's Laboratories Limited · 77 /100
  • LNTH · Lantheus Holdings, Inc. · 96 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$8.22
Change on the day+1.11%
52-week range$5.69–$8.58
Market capitalisation$9.27B—
Price / earnings (trailing)33.77
Shares traded on the day2.3K
Beta (volatility vs the S&P 500)-0.07
Dividends per share (last 12 months)$0.22
Dividend yield (last 12 months)2.69%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $5.80, high $8.31, latest $8.22. 2 reported quarters marked. 1 other dated event marked. $8.31 $5.80 high $8.31 Feb 5, 2026 · Earnings results · no recorded estimate to compare · close $7.351May 13, 2026 · Earnings results · no recorded estimate to compare · close $7.182Nov 10, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $8.113 Oct 17, 2025 Nov 19, 2026 · $8.22 $7.55Oct 17, 2025$7.35Oct 31, 2025$7.36Nov 14, 2025$7.86Nov 28, 2025$7.20Dec 12, 2025$7.47Dec 26, 2025$7.59Jan 9, 2026$7.21Jan 23, 2026$7.35Feb 6, 2026$8.21Feb 20, 2026$7.53Mar 6, 2026$7.30Mar 20, 2026$7.90Apr 2, 2026$7.74Apr 17, 2026$7.39May 1, 2026$7.18May 15, 2026$6.15May 29, 2026$5.87Jun 12, 2026$6.20Jun 26, 2026$6.63Jul 10, 2026$7.10Jul 24, 2026$7.56Aug 7, 2026$7.77Aug 21, 2026$7.47Sep 4, 2026$7.85Sep 18, 2026$7.45Oct 2, 2026$7.70Oct 16, 2026$7.96Oct 30, 2026$8.11Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results
  • · Earnings results
  • · Earnings call · management outlook

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleMar 30, 2027, Ex-dividend date; Jun 1, 2027, Dividend payment date. Spacing is order only and carries no duration.Nov 19, 20261Mar 30, 20272Jun 1, 2027
  1. Ex-dividend dateCompany record
  2. Dividend payment dateCompany record

Management outlook

  • For this fiscal year, as we have already reported to you, we believe that the gross profit margin is going to be controlled within the guidance.

    Terushige Iike · Statement from

How to read these dates

Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations can change.

What to watch next

Other perspectives

Council score for Eisai Co. (ESAIY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Moderate
ROE Weak
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Eisai Co. (ESAIY), and what does it report?

Short answer

Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. Healthcare / Drug Manufacturers Specialty & Generic Headquarters: 4-6-10, Koishikawa, Tokyo, TY, 112-8088, JP. It employs 10,543 people and is led by Haruo Naito. In Q2 FY2026 it reported revenue of ¥235.63B and net income of ¥11.69B. The market values it at $9.27B.

2 · Latest results

What do the latest results show for Eisai Co. (ESAIY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of ¥235.63B.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.31B May 13, 2026
Latest report · revenue estimate
$195.68B May 13, 2026
Latest report · revenue vs estimate
Below estimate May 13, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
May 13, 2026$1.31B$195.68B−$0.0184Not available
Feb 5, 2026$1.43B$212.26B$0.0989Not available
Nov 6, 2025$1.34B$197.61B$0.0610$0.0691
Aug 4, 2025$1.41B$197.60B$0.0900$0.0596
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026¥235.63B¥11.69B¥10.37 (diluted)
Q1 FY2026¥237.42B¥18.48B¥16.15 (diluted)
Q4 FY2025¥209.20B-¥3.31B-¥2.94 (diluted)
Q3 FY2025¥223.91B¥17.49B¥15.50 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Eisai Co. (ESAIY)?

Short answer · as of

The distress and quality screens read Altman Z 3.06 · Piotroski F 8. Trailing ratios: ROE 4.9% · ROA 2.9% · current ratio 2.33 · earnings yield 2.9% · free-cash-flow yield 3.4%.

4 · What to check next?

What should you watch next at Eisai Co. (ESAIY)?

Short answer · as of

Analyst estimates on file carry FY2027 revenue $911.13B · EPS 53.23 · 7 analysts.

What management is planning

Management's statement is quoted under Upcoming events

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$911.13B
EPS estimate
$53.23

Measured against a quoted price of $8.22 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ESAIY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ESAIY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Eisai Co. (ESAIY)?

Read these with our analysis →

What Investors Ask About Eisai Co. (ESAIY) — Healthcare

Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.

How does Lenvima fit into Eisai's business?

Lenvima is a molecularly targeted oncology medicine used across several cancer settings, including combination treatment. It sits within an established oncology portfolio that also includes Halaven and a partnered antibody-drug conjugate program with Bristol Myers Squibb.

What is the ESAIY stock price today?

The last price recorded for Eisai Co., Ltd. (ESAIY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Does ESAIY pay a dividend?

Yes. The dividend yield of Eisai Co., Ltd. (ESAIY) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 40 figures on this page — 1 from SEC filings and earnings calls, 29 from Financial Modeling Prep (FMP), 6 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • FAQ: How does Lenvima fit into Eisai's business?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.